Abstract
SUMMARYRecombinant activated coagulation factor VII (rFVIIa, NovoSeven®) is indicated for the treatment of bleeding episodes or as a prophylactic hemostatic agent during surgery in patients with inhibitor‐complicated hemophilia. Currently, the use of rFVIIa for indications other than hemophilia is being investigated in clinical trials. The original idea behind the development of rFVIIa was that it would function via enhancement of tissue factor‐dependent coagulation. However, the effects of rFVIIa on hemostasis proved to be more complex than initially anticipated. This paper summarizes current data and hypotheses on the mechanism of action of rFVIIa, providing a general model for the molecular basis for the efficacy of rFVIIa in its different applications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
